Five years after COVID-19 transformed the world, scientists understand far more about SARS-CoV-2, vaccines, severe disease, variants, and Long COVID—but important questions remain.
COVID-19: Understanding What We Know After Five Years
More than five years after COVID-19 changed everyday life around the world, our understanding of the disease is very different from what it was in 2020.
Scientists have learned how SARS-CoV-2 spreads, which people are most vulnerable to severe illness, how vaccines reduce serious outcomes, and how to manage many complications more effectively.
But COVID-19 has not simply disappeared.
The virus continues to circulate, evolve, and occasionally cause serious disease—particularly among older adults and people at higher risk. As of 2025, the World Health Organization assessed the global public-health risk from COVID-19 as moderate, noting that hospitalizations and deaths have declined substantially compared with earlier years because of widespread immunity and improved clinical management.
COVID-19 Is Still With Us
The end of the emergency phase of the pandemic did not mean SARS-CoV-2 disappeared.
The virus continues circulating alongside other respiratory viruses, and new variants and subvariants continue to emerge. Most currently monitored variants descend from the Omicron lineage.
For many people, infection today is less likely to result in severe disease than during the earliest years of the pandemic. That’s partly because immunity has increased through vaccination and previous infections, while doctors have also gained experience treating COVID-19.
However, lower average risk does not mean zero risk.
Older adults, people with certain medical conditions, and immunocompromised individuals remain more vulnerable to severe outcomes.
What Have We Learned About Vaccines?
One of the biggest scientific achievements of the pandemic was the rapid development of effective COVID-19 vaccines.
Five years of accumulated safety data have provided substantial evidence that currently available mRNA and protein-based vaccines have an acceptable safety profile. Serious adverse events are rare compared with the billions of doses administered globally.
The most important benefit is protection against severe disease, hospitalization, and death.
Vaccines are not perfect at preventing every infection, and protection against infection can decrease as immunity wanes and the virus evolves. That’s why vaccine formulations can be updated to better match circulating variants.
Current vaccination recommendations increasingly focus on people at greatest risk rather than treating COVID-19 vaccination as a one-size-fits-all approach. WHO’s 2026 recommendations emphasize routine vaccination for groups at particularly high risk of severe disease, with country-specific policies determining details.
Variants Continue to Evolve
SARS-CoV-2 changes as it replicates.
During the pandemic, the world became familiar with names such as Alpha, Delta, and Omicron. Omicron subsequently gave rise to numerous subvariants.
The important lesson is that the virus can continue changing even when population immunity is high.
Fortunately, the variants circulating in recent years have generally not produced the same level of severe disease seen with some earlier variants. WHO reported that most current variants are descendants of JN.1 and have demonstrated immune escape without evidence of increased disease severity.
Continued genomic surveillance remains important because future changes cannot be predicted with certainty.
Long COVID Remains One of the Biggest Unanswered Questions
Perhaps one of the most important discoveries of the past five years is that COVID-19 can have effects that persist well beyond the initial infection.
Long COVID, also called post-COVID-19 condition, can involve multiple body systems.
Symptoms may include:
- Persistent fatigue
- Shortness of breath
- Problems with memory or concentration
- Sleep difficulties
- Muscle or joint pain
- Persistent cough
- Chest discomfort
- Changes in smell or taste
WHO estimates that approximately 6% of people who have COVID-19 develop post-COVID-19 condition, although estimates vary depending on the population and definition used.
Long COVID can occur after an infection that was mild, and symptoms can persist for months or longer. The CDC describes it as a chronic condition that can sometimes cause significant limitations or disability.
Researchers still don’t fully understand why some people develop Long COVID while others recover completely.
There is also no single approved treatment that works for everyone. Medical care generally focuses on evaluating symptoms, ruling out other causes, managing specific problems, and providing rehabilitation or supportive care when appropriate.
Treatment Has Improved
Doctors now have much more experience recognizing and treating severe COVID-19 than they did in early 2020.
Healthcare professionals understand better which patients are at high risk, how the disease can affect multiple organs, and when supportive care or antiviral treatment may be appropriate.
This improved clinical management is one reason COVID-19 outcomes have changed considerably since the first years of the pandemic. WHO specifically identifies improved clinical management, along with immunity, as contributing to declining hospitalizations and deaths.
What We Still Don’t Know
Despite enormous scientific progress, important questions remain.
Researchers are still studying:
The origins of SARS-CoV-2
The precise origins and pathway by which SARS-CoV-2 entered human populations remain an area of continuing investigation.
Why some people develop Long COVID
Researchers are investigating immune-system changes, viral persistence, inflammation, and other possible mechanisms, but there isn’t one explanation that accounts for every case.
How the virus will evolve
Future variants cannot be predicted precisely. Continued surveillance is therefore important, particularly because reduced testing and genomic sequencing can make it harder to identify changes quickly.
How to provide lasting protection
Current vaccines are highly valuable for preventing severe outcomes, but immunity decreases over time and the virus continues evolving. Scientists continue working on strategies that could provide broader or longer-lasting protection.
What Should People Take Away From Five Years of Evidence?
Perhaps the biggest lesson is that COVID-19 is no longer the same public-health threat it was in 2020—but it is not irrelevant either.
For many healthy people, infection may now be manageable without hospitalization. But vulnerable individuals can still become seriously ill, and Long COVID remains a genuine concern.
The most useful approach is therefore neither panic nor complacency.
People at increased risk should discuss appropriate vaccination and prevention strategies with their healthcare professionals. Staying home when sick, improving ventilation in crowded indoor settings, and following local public-health recommendations can also help reduce transmission.
The Bottom Line
Five years of research have transformed what we know about COVID-19.
We understand much more about the virus, vaccines, severe disease, variants, and long-term complications. Vaccination and prior immunity have dramatically changed the landscape, while better medical care has improved outcomes.
But the story isn’t finished.
COVID-19 continues to evolve, Long COVID remains incompletely understood, and researchers are still watching for what comes next.
The goal now is not to live in fear of the virus—but to use what five years of evidence have taught us to make informed decisions and protect people who remain most vulnerable.